Xenon's Losses Widen 43% Amid Soaring R&D Costs

TL;DR

**XENE is burning cash at an alarming rate, and while R&D is up, they need a win with azetukalner or more capital soon.**

AI Summary

Xenon Pharmaceuticals Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $240,649 thousand, up from $168,645 thousand in the same period of 2024, representing a 42.7% increase. This was primarily driven by a substantial rise in research and development expenses, which climbed to $213,239 thousand in 2025 from $150,922 thousand in 2024, an increase of 41.3%. General and administrative expenses also rose to $57,564 thousand from $50,899 thousand. Collaboration revenue, which was zero in 2024, contributed $7,500 thousand in 2025. The company's cash, cash equivalents, and marketable securities decreased to $555,256 thousand as of September 30, 2025, from $754,903 thousand at December 31, 2024, indicating significant cash burn. Despite these losses, management expects current cash and marketable securities to fund operations for at least the next 12 months. The company continues to focus on the successful development of azetukalner, which is highlighted as a substantial dependency and risk.

Why It Matters

For investors, Xenon's escalating net loss and significant cash burn, with cash and marketable securities dropping by nearly $200 million, signal increased financial risk and a continued reliance on future funding rounds. Employees face potential uncertainty if development programs for key candidates like azetukalner falter, impacting job security and project continuity. Customers, particularly patients awaiting new neuroscience therapeutics, are directly affected by the success or failure of Xenon's clinical trials and its ability to bring new drugs to market. In the competitive biopharmaceutical landscape, Xenon's substantial R&D investment, while necessary for innovation, must yield tangible results to maintain its market position against larger, more financially robust competitors.

Risk Assessment

Risk Level: high — Xenon Pharmaceuticals Inc. reported an accumulated deficit of $1,140,119 thousand as of September 30, 2025, and a net loss of $240,649 thousand for the nine months ended September 30, 2025. The company's cash, cash equivalents, and marketable securities decreased by $199,647 thousand from December 31, 2024, to September 30, 2025, indicating a high burn rate and significant reliance on future financing, which may not be available on acceptable terms.

Analyst Insight

Investors should closely monitor the progress of Xenon's lead product candidate, azetukalner, and any announcements regarding new collaboration agreements or financing rounds. Given the high cash burn and increasing losses, a speculative position might be considered only if there are clear positive clinical trial catalysts or a significant capital infusion. Otherwise, caution is advised due to the substantial financial risks.

Financial Highlights

debt To Equity

N/A

revenue

$7,500,000

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$240,649,000

eps

N/A

gross Margin

N/A

cash Position

$555,256,000

revenue Growth

+N/A%

Revenue Breakdown

Key Numbers

• $240.6M — Net Loss (Increased from $168.6M in 2024 for the nine months ended September 30, 2025)
• $213.2M — Research and Development Expenses (Increased from $150.9M in 2024 for the nine months ended September 30, 2025)
• $1,140.1M — Accumulated Deficit (As of September 30, 2025, indicating significant historical losses)
• $555.3M — Cash, Cash Equivalents, and Marketable Securities (As of September 30, 2025, down from $754.9M at December 31, 2024)
• 42.7% — Increase in Net Loss (Year-over-year increase for the nine months ended September 30, 2025)
• 41.3% — Increase in R&D Expenses (Year-over-year increase for the nine months ended September 30, 2025)
• $7.5M — Collaboration Revenue (Generated for the nine months ended September 30, 2025, up from $0 in 2024)
• 77,120,168 — Common Shares Outstanding (As of September 30, 2025)

Key Players & Entities

• Xenon Pharmaceuticals Inc. (company) — Registrant and neuroscience-focused biopharmaceutical company
• azetukalner (product) — Key product candidate whose successful development is crucial to the business
• SEC (regulator) — United States Securities and Exchange Commission
• FDA (regulator) — Food and Drug Administration
• EMA (regulator) — European Medicines Agency
• $1,140,119 thousand (dollar_amount) — Accumulated deficit as of September 30, 2025
• $240,649 thousand (dollar_amount) — Net loss for the nine months ended September 30, 2025
• $213,239 thousand (dollar_amount) — Research and development expenses for the nine months ended September 30, 2025
• $555,256 thousand (dollar_amount) — Cash, cash equivalents and marketable securities as of September 30, 2025
• Nasdaq Stock Market LLC (company) — Exchange where common shares are registered

FAQ

Risk Factors

• Dependency on Azetukalner Development [high — operational]: The company's success is substantially dependent on the development of azetukalner. Any delays, setbacks, or failure in its development or commercialization would materially and adversely affect the company's business, financial condition, and results of operations.
• Significant Net Loss and Cash Burn [high — financial]: Xenon reported a net loss of $240,649,000 for the nine months ended September 30, 2025, a 42.7% increase from $168,645,000 in the same period of 2024. This substantial cash burn, coupled with a decrease in cash, cash equivalents, and marketable securities from $754,903,000 at December 31, 2024, to $555,256,000 at September 30, 2025, presents a financial risk.
• Insufficient Funding for Long-Term Operations [high — financial]: While management expects current cash and marketable securities to fund operations for at least the next 12 months, the significant increase in net loss and R&D expenses suggests a continued need for substantial funding. Failure to secure additional financing could jeopardize ongoing operations.
• High Research and Development Expenses [medium — operational]: R&D expenses increased by 41.3% to $213,239,000 for the nine months ended September 30, 2025, from $150,922,000 in the comparable period of 2024. This significant investment, while necessary for drug development, contributes heavily to the company's net loss and requires careful management.
• Increasing General and Administrative Expenses [low — operational]: General and administrative expenses rose to $57,564,000 from $50,899,000 for the nine months ended September 30, 2025, compared to the same period in 2024. While not as substantial as R&D, this increase adds to the overall operating costs.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Xenon Pharmaceuticals rely heavily on innovation and successful clinical trials to bring new therapies to market. The competitive landscape is intense, with many players vying for market share in therapeutic areas. Success often hinges on securing substantial funding to navigate the complex development and approval processes.

Regulatory Implications

Xenon Pharmaceuticals operates within a highly regulated environment. The development and approval of its drug candidates, such as azetukalner, are subject to stringent review by regulatory bodies like the FDA. Any delays or failures in the regulatory process can significantly impact timelines and financial viability. Compliance with evolving healthcare regulations and data privacy laws is also critical.

What Investors Should Do

1. Monitor R&D progress and clinical trial results for azetukalner closely.
2. Assess the company's cash burn rate and future funding needs.
3. Analyze the growth and sustainability of collaboration revenue.
4. Evaluate management's ability to control operating expenses, particularly G&A.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported a net loss of $240.6M, driven by increased R&D expenses of $213.2M. Cash, cash equivalents, and marketable securities stood at $555.3M.
• 2024-09-30: Nine months ended September 30, 2024 — Reported a net loss of $168.6M, with R&D expenses of $150.9M. Collaboration revenue was $0.
• 2024-12-31: As of December 31, 2024 — Cash, cash equivalents, and marketable securities were $754.9M.

Glossary

Net Loss

The total expenses incurred by a company exceed its total revenues over a specific period. (Indicates the company's profitability, with Xenon experiencing a significant and increasing net loss.)

Research and Development Expenses (R&D)

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (A major expense driver for Xenon, reflecting significant investment in drug development, particularly azetukalner.)

Collaboration Revenue

Revenue generated from partnerships or agreements with other companies for the development or commercialization of products. (A new revenue stream for Xenon in 2025, indicating potential progress in partnerships.)

Cash, Cash Equivalents, and Marketable Securities

Highly liquid assets that can be readily converted into cash, representing a company's short-term financial flexibility. (Shows Xenon's available liquidity, which has decreased significantly, highlighting cash burn.)

Accumulated Deficit

The cumulative net losses of a company since its inception, representing the total historical losses that have not been offset by profits. (At $1,140.1M as of September 30, 2025, it underscores Xenon's long-standing history of operating at a loss.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Xenon Pharmaceuticals reported a significant 42.7% increase in net loss to $240.6M, compared to $168.6M in the prior year period. This was primarily driven by a 41.3% surge in R&D expenses to $213.2M. While collaboration revenue emerged at $7.5M, up from $0, it was insufficient to offset the rising operational costs. The company's cash position also declined substantially from $754.9M at the end of 2024 to $555.3M, indicating an accelerated cash burn.

Filing Documents

• xene-20250930.htm (10-Q) — 2647KB
• xene-ex31_1.htm (EX-31.1) — 17KB
• xene-ex31_2.htm (EX-31.2) — 17KB
• xene-ex32_1.htm (EX-32.1) — 12KB
• xene-ex32_2.htm (EX-32.2) — 11KB
• 0001193125-25-262646.txt ( ) — 8882KB
• xene-20250930.xsd (EX-101.SCH) — 885KB
• xene-20250930_htm.xml (XML) — 1769KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss 4 Condensed Consolidated Statements of Shareholders' Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 14

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 22

Controls and Procedures

Item 4. Controls and Procedures 22

OTHER INFORMATION

PART II. OTHER INFORMATION 24

Legal Proceedings

Item 1. Legal Proceedings 24

Risk Factors

Item 1A. Risk Factors 24

Other Information

Item 5. Other Information 64

Exhibits

Item 6. Exhibits 65

SIGNATURES

SIGNATURES 66 In this Quarterly Report on Form 10-Q, "we," "our," "us," "Xenon," and "the Company" refer to Xenon Pharmaceuticals Inc. and its subsidiary. "Xenon" and the Xenon logo are the property of Xenon Pharmaceuticals Inc. and are registered in the United States and used or registered in various other jurisdictions. This report contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this report may appear without the or symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. - 1 - Risk Factors Summary Our business is subject to numerous risks and uncertainties, including those highlighted in the section of this report captioned "Risk Factors." The following is a summary of the principal risks we face: We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We will need to raise additional funding, which may not be available on acceptable terms, if at all. Failure to obtain capital when needed may force us to delay, limit or terminate our product discovery and development programs or commercialization efforts or other operations. Our business substantially depends upon the successful development of azetukalner. If we are unable to obtain regulatory approval for, and successfully commercialize, azetukalner, our business may be materially harmed. Clinical studies may fail to demonstrate adequately the safety and efficacy of our, or our collaborators', product candidates at any stage of clinical development. Terminating the development of any of our, or our collaborat

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

Fina ncial Statements

Item 1. Fina ncial Statements XENON PHARMACEUTICALS INC. Condensed Consolidated Ba lance Sheets (Unaudited) (Expressed in thousands of U.S. dollars except share amounts) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 104,514 $ 142,712 Marketable securities (note 5) 357,754 484,193 Other receivables 812 1,469 Prepaid expenses and other current assets 17,057 6,890 Total current assets 480,137 635,264 Marketable securities, long-term (note 5) 92,988 127,496 Operating lease right-of-use asset, net (note 6) 6,960 7,939 Property, plant and equipment, net 8,887 10,278 Deferred tax assets 11,750 9,666 Prepaid expenses, long-term 7,114 7,496 Total assets $ 607,836 $ 798,139 Liabilities and shareholders' equity Current liabilities: Accounts payable and accrued liabilities (note 7) $ 36,840 $ 34,221 Operating lease liability (note 6) 1,495 1,369 Total current liabilities 38,335 35,590 Operating lease liability, long-term (note 6) 6,832 7,646 Other liabilities, long-term 3,158 — Total liabilities 48,325 43,236 Shareholders' equity: Common shares, without par value; unlimited shares authorized; issued and outstanding: 77,120,168 (December 31, 2024 - 76,416,086 ) (note 8) 1,475,371 1,456,836 Additional paid-in capital 223,782 199,149 Accumulated deficit ( 1,140,119 ) ( 899,470 ) Accumulated other comprehensive income (loss) 477 ( 1,612 ) Total shareholders' equity 559,511 754,903 Total liabilities and shareholders' equity $ 607,836 $ 798,139 Commitments and contingencies (note 11) See accompanying notes to the condensed consolidated financial statements. - 3 - XENON PHARMACEUTICALS INC. Condensed Consolidated St atements of Operations and Comprehensive Loss (Unaudited) (Expressed in thousands of U.S. dollars except share and per share amounts)

View Full Filing

View this 10-Q filing on SEC EDGAR